Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.

 

CURRENTLY ENROLLING CLINICAL TRIALS

HOLLYWOOD NEUROLOGY
To participate or refer a patient, please call 954-366-0277.

Clinical Coordinators: Jorge Riveros, IMG, CCRC • Rebecca Nembhard, CCRC • Lucy Vargas, MA, CRC

Eisai-CLARITY: Early Alzheimer’s Disease – An 18-month randomized study to evaluate the safety and efficacy of an infused investigational medication vs. placebo in subjects 50-90 years of age with Mild Cognitive Impairment or early Alzheimer’s Disease. Visits are every 2 weeks, must have a study partner. 2-year Open label extension to follow for patients completing the double-blind study. (MMSE 22-30)

T3D PIONEER: Mild to moderate Alzheimer’s Disease – A 28-week randomized study to evaluate the efficacy, safety and tolerability of an oral investigational medication vs. placebo in subjects with mild to moderate Alzheimer’s Disease, must have a study partner, ages 50-90. (MMSE 16-26)

Impax: Parkinson’s Disease – A Randomized controlled study to compare the safety and efficacy of an oral drug with Immediate Release-Carbidopa-Levodopa in Parkinson’s disease patients with motor fluctuations.

Neuraly: Early Parkinson’s Disease – A 36-week randomized double-blind study to evaluate the efficacy, safety and tolerability of an oral medication vs. placebo in Early Parkinson’s Disease, ages 30-80.

Sage: Essential Tremor-A 6 week double-blind, placebo controlled, randomized study evaluating the efficacy, safety and tolerability of Sage-324 in the treatment of individuals with essential tremor who are ages 18-80.

 

SUNRISE OFFICE NEUROLOGY
To participate or refer a patient Call 954-475-8171, ext 146 (Fanny) or ext 138 (Adriana)

Clinical Coordinators: Fanny Gully, CRC and Adriana Araujo, CRC

Eisai CLARITY: Early Alzheimer’s Disease – An 18-month randomized study to evaluate the safety and efficacy of an infused investigational medication vs. placebo in subjects 50-90 years of age with Mild Cognitive Impairment or early Alzheimer’s Disease. Visits are every 2 weeks, must have a study partner. 2-year Open label extension to follow for patients completing the double-blind study.  (MMSE 22-30)

Acadia: Parkinson’s Disease 063 – A 16-week Open label study of the Effects of treatment with Pimavanserin on Activities of Daily Living in subjects with Parkinson’s Disease Psychosis, must have a study partner

Impax: Parkinson’s Disease – A Randomized controlled study to compare the safety and efficacy of an oral drug with Immediate Release-Carbidopa-Levodopa in Parkinson’s disease patients with motor fluctuations.

Aptinyx: Parkinson’s Disease – A study to evaluate NYX-458 in subjects with Mild Cognitive Impairment associated with Parkinson’s Disease, must have a study partner and be between 50-80 years of age.

Acadia: Parkinson’s Disease 056 -A placebo-controlled study to evaluate Safety and Daytime Sedation in subjects with Parkinson’s Disease with Neuropsychiatric Symptoms with Pimavanserin or Low Dose Quetiapine. Must have a study partner and be at least 50 years old.

Takeda: Parkinson’s Disease-A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral TAK-071 in Parkinson’s patients with Cognitive Impairment and an Elevated Risk of Falls for people 40-75 years of age.

Satsuma: Acute Migraine-An open label 12-month study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in Acute Treatment of Migraine

 

SUNRISE OFFICE NEUROLOGY – MS STUDIES
To participate or refer a patient –Call 954-475-8171 Ext 134 (Michele)

Clinical Coordinators: Michele Fistel, LPN, CCRC • Adriana Araujo,CCRC • Fanny Gully CRC

Novartis: EXCHANGE – Advancing Relapsing-Remitting MS – A 6 month open label study for a new oral medication for MS, patients wanting to switch from taking beta-interferons, glatiramer acetate, fingolimod, dimethyl fumarate, or teriflunomide (must have been on these medications for at least 3 months). Patients must have had a relapse in the last 12 months. Extension study to follow, for patients completing the 6-month study. Participants must be between 18-65 years old.

Sanofi- Gemini 2: Relapsing MS— (SPMS or RRMS) A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis (GEMINI 2). Participants must be 18-55 years old.

Novartis-Artios: –Relapsing MS— (SPMS or RRMS) A single-arm, prospective, open-label study to evaluate ofatumumab treatment effectiveness and patient reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy. Participants must be 18-60 years old.